Norwegian startup Vitroscope secures $7 million to scale living human tissue technology

Norwegian startup Vitroscope has raised $7 million to scale its technology for working with living human tissue. The funding is aimed at expanding a platform that runs experiments on live human tissue for drug discovery and development.

The only detailed account of the company comes from a quote by Markus Feuerecker, Founding and Managing Partner at YZR Capital, an investor in the company. He says drug discovery and development need data that lets researchers actually predict how patients will respond, and that Vitroscope generates that data at the source. He describes the platform as physical AI infrastructure: each experiment on living human tissue produces proprietary, comparable data that compounds over time.

Feuerecker calls Vitroscope a key building block in rewiring the pharma value chain, turning cell-level insight into something useful for the industry. The quote is cut off at that point, so his full argument is not available.

The text I was given does not include the names of other investors, the structure of the round, the company's founders, or any customers or partners. It also gives no timeline for how the money will be used. What it does establish is the size of the round, the company's Norwegian base, and the investor's view that tissue-based, patient-relevant data is what drug developers need in order to predict human responses, rather than relying on less direct models.

The news matters because it adds to a run of funding rounds for Nordic AI and deep tech startups, and it points to investor interest in AI infrastructure built on biological data generated in the lab.